The first pneumococcal conjugate vaccine (PCV) was licensed more than 25 years ago in the USA and Europe, but its marketing authorisation was based on efficacy studies using a 3+1 dosing regimen, ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at https://investors.vaxcyte.com. A replay of the webcast will be available for ...

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

Against influenza and COVID-19 certainly, and for the elderly and the more susceptible, against respiratory syncytial virus (RSV) and pneumococcal pneumonia, too. Vaccines, while not absolutely ...

Besides all serotypes covered by the Pfizer shot, VAX-31 contains 11 additional serotypes ... designed to prevent more than 95% of invasive pneumococcal disease circulating in adults 50 and ...

For all 11 incremental serotypes unique to VAX-31 ... The FDA recently approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) as the first pneumococcal ...

Also Read: Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots – Analyst ... immune responses compared to PCV20. For all 11 incremental serotypes unique to VAX-31 ...

In fact, in the second quarter, we grew 11% year-over-year ex exchange ... We're now in 31 markets, competing really well in the marketplace for patients with pneumococcal disease. And likewise, we ...

Vaxcyte’s shot covers an additional 11 strains than Prevnar 20 ... indicates Wall Street sees it as a potential competitor to pneumococcal vaccines from Pfizer, Merck & Co. and GSK.

We recently compiled a list of the 10 Best Defensive Stocks According to Reddit. In this article, we will look at where Merck ...